2022 Develop Marketing San Diego 
TechCrunch LA
FEBRUARY 6, 2022
Last week, we talked about about the “de-stonkifying” of the market. The company’s stock tanked by more than 26 percent, representing a $230 billion reduction in market cap and a $31 billion drop in Zuckerberg’s personal net worth. — Lucas Matney (@lucasmtny) February 6, 2022. other things.
Xconomy
AUGUST 26, 2020
Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector is riding high. Waltham, MA-based Dyne is developing treatments for rare, inherited muscle disorders.
Expert insights. Personalized for you.
246 
Let's personalize your content